Induction of trained immunity by influenza vaccination - impact on COVID-19.

Non-specific protective effects of certain vaccines have been reported, and long-term boosting of innate immunity, termed trained immunity, has been proposed as one of the mechanisms mediating these effects. Several epidemiological studies suggested cross-protection between influenza vaccination and...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Priya A Debisarun, Katharina L Gössling, Ozlem Bulut, Gizem Kilic, Martijn Zoodsma, Zhaoli Liu, Marina Oldenburg, Nadine Rüchel, Bowen Zhang, Cheng-Jian Xu, Patrick Struycken, Valerie A C M Koeken, Jorge Domínguez-Andrés, Simone J C F M Moorlag, Esther Taks, Philipp N Ostermann, Lisa Müller, Heiner Schaal, Ortwin Adams, Arndt Borkhardt, Jaap Ten Oever, Reinout van Crevel, Yang Li, Mihai G Netea
Formato: article
Lenguaje:EN
Publicado: Public Library of Science (PLoS) 2021
Materias:
Acceso en línea:https://doaj.org/article/fc082979274c412fbfb54b69a2f5e96c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
Descripción
Sumario:Non-specific protective effects of certain vaccines have been reported, and long-term boosting of innate immunity, termed trained immunity, has been proposed as one of the mechanisms mediating these effects. Several epidemiological studies suggested cross-protection between influenza vaccination and COVID-19. In a large academic Dutch hospital, we found that SARS-CoV-2 infection was less common among employees who had received a previous influenza vaccination: relative risk reductions of 37% and 49% were observed following influenza vaccination during the first and second COVID-19 waves, respectively. The quadrivalent inactivated influenza vaccine induced a trained immunity program that boosted innate immune responses against various viral stimuli and fine-tuned the anti-SARS-CoV-2 response, which may result in better protection against COVID-19. Influenza vaccination led to transcriptional reprogramming of monocytes and reduced systemic inflammation. These epidemiological and immunological data argue for potential benefits of influenza vaccination against COVID-19, and future randomized trials are warranted to test this possibility.